Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.

Autor:	Kocas-Kilicarslan ZN; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Cetin Z; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Faccioli LAP; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Motomura T; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Amirneni S; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Diaz-Aragon R; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Florentino RM; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Sun Y; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.; School of Medicine, Tsinghua University, Beijing, China., Pla-Palacin I; University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania., Xia M; University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania., Miedel MT; University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania., Kurihara T; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Hu Z; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Ostrowska A; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.; Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania., Wang Z; Department of Statistics, University of Pittsburgh, Pittsburgh, Pennsylvania., Constantine R; Discovery Life Sciences, Huntsville, Alabama., Li A; Discovery Life Sciences, Huntsville, Alabama., Taylor DL; University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania.; Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania., Behari J; Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, Pennsylvania., Soto-Gutierrez A; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.; University of Pittsburgh Drug Discovery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.; Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania.; McGowan Institute for Regenerative Medicine, Pittsburgh, Pennsylvania., Tafaleng EN; Department of Pathology, Center for Transcriptional Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Jazyk:	angličtina
Zdroj:	Gastro hep advances [Gastro Hep Adv] 2024; Vol. 3 (1), pp. 67-77. Date of Electronic Publication: 2023 Oct 05.
DOI:	10.1016/j.gastha.2023.09.011
Abstrakt:	Background and Aims: Chronic liver injury that results in cirrhosis and end-stage liver disease (ESLD) causes more than 1 million deaths annually worldwide. Although the impact of genetic factors on the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) has been previously studied, their contribution to the development of ESLD remains largely unexplored. Methods: We genotyped 6 MASLD-associated polymorphisms in healthy (n = 123), metabolic dysfunction-associated steatohepatitis (MASH) (n = 145), MASLD-associated ESLD (n = 72), and ALD-associated ESLD (n = 57) cohorts and performed multinomial logistic regression to determine the combined contribution of genetic, demographic, and clinical factors to the progression of ESLD. Results: Distinct sets of factors are associated with the progression to ESLD. The PNPLA3 rs738409:G and TM6SF2 rs58542926:T alleles, body mass index (BMI), age, and female sex were positively associated with progression from a healthy state to MASH. The PNPLA3 rs738409:G allele, age, male sex, and having type 2 diabetes mellitus were positively associated, while BMI was negatively associated with progression from MASH to MASLD-associated ESLD. The PNPLA3 rs738409:G and GCKR rs780094:T alleles, age, and male sex were positively associated, while BMI was negatively associated with progression from a healthy state to ALD-associated ESLD. The findings indicate that the PNPLA3 rs738409:G allele increases susceptibility to ESLD regardless of etiology, the TM6SF2 rs58542926:T allele increases susceptibility to MASH, and the GCKR rs780094:T allele increases susceptibility to ALD-associated ESLD. Conclusion: The PNPLA3 , TM6SF2 , and GCKR minor alleles influence the progression of MASLD-associated or ALD-associated ESLD. Genotyping for these variants in MASLD and ALD patients can enhance risk assessment, prompting early interventions to prevent ESLD. Competing Interests: Conflicts of Interest: These authors disclose the following: Alejandro Soto-Gutierrez is an inventor on a patent application that describes the use of transcription factors to treat chronic liver failure (US20140249209). Edgar N. Tafaleng and Alejandro Soto-Gutierrez are inventors on a provisional patent application related to methods to enhance hepatic functions in human failing livers (PCT/US2020/055500). Alejandro Soto-Gutierrez is a co-founder and has a financial interest in Von Baer Wolff, Inc, a company focused on biofabrication of autologous human hepatocytes from stem cells technology. Alejandro Soto-Gutierrez and Alina Ostrowska are co-founders and have a financial interest in Pittsburgh ReLiver Inc, a company focused on reprogramming hepatocytes in liver failure. Jaideep Behari has received research grant funding from Gilead, Pfizer, and Endra Life Sciences. His institution has clinical research contracts with Intercept, Pfizer, Galectin, Exact Sciences, Inventiva, Enanta, Shire, Gilead, Allergan, Celgene, Galmed, Rhythm, and Genentech. All these interests are managed by the Conflict of Interest Office at the University of Pittsburgh in accordance with their policies. The remaining authors disclose no conflicts.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu